Skip to main content

Table 1 Distribution of variables by BMI category (non-obese, obese, and severely obese women)

From: Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis

  BMI <30.0 BMI 30 to 34.9 BMI ≥ 35.0  
  Number (%) Number (%) Number (%) P-valuea
Age at diagnosis, years     <0.001
20 to 44 1,473 (34.2%) 138 (14.6%) 56 (13.0%)  
45 to 54 1,599 (37.1%) 284 (30.1%) 153 (35.5%)  
55 to 64 932 (21.6%) 364 (38.5%) 147 (34.1%)  
65 to 76 303 (7.0%) 159 (16.8%) 75 (17.4%)  
Median (percentiles 25 to 75) 48 (42 to 56) 56 (49 to 62) 55 (49 to 62)  
Menopausal status     <0.001
Postmenopausal 1,737 (40.3%) 631 (66.8%) 293 (68.0%)  
Premenopausal 2,570 (59.7%) 314 (33.2%) 138 (32.0%)  
Histology     0.730
Ductal 3,645 (84.6%) 788 (83.4%) 376 (87.2%)  
Lobulillar 385 (8.9%) 93 (9.8%) 32 (7.4%)  
Mixed 46 (1.1%) 12 (1.3%) 4 (0.9%)  
Others 230 (5.3%) 52 (5.5%) 19 (4.4%)  
Unknown 1 (0.0%) 0 (0.0%) 0 (0.0%)  
Histological grade     0.054
1 384 (8.9%) 81 (8.6%) 34 (7.9%)  
2 1,792 (41.6%) 416 (44.0%) 196 (45.5%)  
3 1,823 (42.3%) 381 (40.3%) 187 (43.4%)  
Unknown 308 (7.1%) 67 (7.1%) 14 (3.2%)  
Pathologic primary tumor size     <0.001
T1 2,192 (50.9%) 423 (44.8%) 179 (41.5%)  
T2 1,948 (45.2%) 485 (51.3%) 232 (53.8%)  
T3 167 (3.9%) 37 (3.9%) 20 (4.6%)  
Nodes     0.021
Negative 2,278 (52.9%) 487 (51.5%) 198 (45.9%)  
Positive 2,029 (47.1%) 458 (48.5%) 233 (54.1%)  
Estrogen receptor     0.647
Negative 1,398 (32.5%) 321 (34.0%) 137 (31.8%)  
Positive 2,899 (67.3%) 623 (65.9%) 291 (67.5%)  
Unknown 10 (0.2%) 1 (0.1%) 3 (0.7%)  
Progesterone receptor     0.199
Negative 1,654 (38.4%) 373 (39.5%) 149 (34.6%)  
Positive 2,576 (59.8%) 558 (59.0%) 276 (64.0%)  
Unknown 77 (1.8%) 14 (1.5%) 6 (1.4%)  
Human epidermal growth factor-2 status     0.030
Negative 3,036 (70.5%) 690 (73.0%) 329 (76.3%)  
Positive 656 (15.2%) 123 (13.0%) 51 (11.8%)  
Unknown 615 (14.3%) 132 (14.0%) 51 (11.8%)  
Type of surgery     0.071
Mastectomy 2,021 (46.9%) 405 (42.9%) 195 (45.2%)  
Conservative 2,286 (53.1%) 540 (57.1%) 236 (54.8%)  
Hormonotherapy     0.334
None 1,068 (24.8%) 256 (27.1%) 115 (26.7%)  
Yes 3,081 (71.5%) 664 (70.3%) 300 (69.6%)  
Unknown 158 (3.7%) 25 (2.6%) 16 (3.7%)  
Adverse events (grades 3,4)     0.498
No 2,565 (59.6%) 578 (61.2%) 250 (58.0%)  
Yes 1,742 (40.4%) 367 (38.8%) 181 (42.0%)  
Initial under-treatment (in the first dose) b     <0.001
No 4,205 (97.6%) 922 (97.6%) 405 (94.0%)  
Yes 102 (2.4%) 23 (2.4%) 26 (6.0%)  
Per type of treatmentc     
Epirubicin <85% 5 (0.5%) 5 (2.3%) 4 (4.0%) 0.002
Cyclophosphamide <85% 12 (0.3%) 4 (0.4%) 8 (1.9%) <0.001
Fluorouracil <85% 8 (0.2%) 4 (0.5%) 7 (2.2%) <0.001
Doxorubicin <85% 4 (0.1%) 3 (0.4%) 7 (2.1%) <0.001
Docetaxel <85% 24 (2.5%) 5 (2.4%) 6 (5.4%) 0.199
Paclitaxel <85% 62 (5.2%) 11 (4.2%) 7 (6.7%) 0.604
Overall undertreatment b     <0.001
No 3,903 (90.6%) 820 (86.8%) 360 (83.5%)  
Yes 404 (9.4%) 125 (13.2%) 71 (16.5%)  
Per type of treatment c     
Epirubicin <85% 50 (5.5%) 15 (6.8%) 13 (13.1%) 0.011
Cyclophosphamide <85% 213 (4.9%) 49 (5.2%) 34 (7.9%) 0.032
Fluorouracil <85% 132 (3.9%) 25 (3.4%) 24 (7.5%) 0.005
Doxorubicin <85% 160 (4.7%) 40 (5.5%) 26 (7.8%) 0.040
Docetaxel <85% 117 (15.8%) 39 (18.9%) 10 (9.9%) 0.068
Paclitaxel <85% 159 (13.3%) 59 (22.6%) 26 (25.0%) <0.001
  1. aP-values computed excluding women without information in the corresponding variable; bdefined as total dose received lower than 85% of the theoretical dose prescribed; cpercentages including only women receiving the corresponding type of treatment. BMI, body mass index.